Photo: Dr Anne Collins,General Manager Instruments, Sensors and Devices, Trajan Scientific and Medical, Adelaide. Fiber drums and the microscope system for fiber internal structure analysis.
Melbourne, Victoria, Australia - 27 November 2015
Trajan Scientific and Medical (Trajan) has announced the opening of a new Business Unit - Instruments, Sensors and Devices, to be located at the University of Adelaide’s Institute for Photonics and Advanced Sensing (IPAS). Along with the new capabilities existing on that site such as glass modification and extrusion, the new Business Unit will have global responsibilities for new devices such as the recently revealed hemaPEN™ for dried blood spot sampling.
This announcement comes just two months after Trajan’s landmark strategic collaboration with the University of Adelaide, supported by the South Australian Government, was revealed. This collaboration sees the realization of the IPAS research and development and manufacturing hub based on a new generation of specialty glass products for the global science and medical equipment market, helping scientists to commercialize their research into products that ultimately benefit human health and wellbeing.
Chief Executive Officer of Trajan, Stephen Tomisich says the company’s new Instruments, Sensors and Devices Business Unit marks another key milestone in Trajan’s journey into technologies that impact human wellbeing.
“The opening of the Instruments, Sensors and Devices Business Unit is a significant milestone for Trajan as we expand our footprint from our historical manufacturing hub in Melbourne, Victoria. The combination of the location in Adelaide, the collaboration with IPAS and the University, and the expansion of technical capabilities puts us in a strong position to realize our vision of enriching wellbeing,” said Mr Tomisich.
Dr Anne Collins has been announced as the General Manager of the Instruments, Sensors and Devices Business Unit. With a PhD in Biochemical Engineering from the University College London, UK and a MBA from the University of Adelaide, Dr Collins possesses more than 20 years international experience in the pharmaceutical and life science industry in roles. She is supported by Principal Scientist (Photonics), Dr Herbert Foo.
Dr Collins comments the role of the new Business Unit is to lead the transition of Trajan into the new era of portable, sensitive and selective sensors and devices.
“Our vision is to develop and commercialize such products in to global health, food and environmental markets, underpinned by rigorous science and excellence in product development and manufacture,” she said.
Trajan’s goal is for the hub to become a global center of excellence for sensing and device technologies. The company’s focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements - especially those that can lead to portability, miniaturization and affordability.
Photos: Dr Herbert Foo with a lead silicate glass drop, from the 4 meter fiber drawing tower for soft glass and polymer fibers fabrication with UV lamp for in-line fiber coating.
Photos: Dr Anne Collins with preforms of tellurite glass photonics crystal fiber and bismuth glass capillary.
Trajan Press Release [PDF]
Media Contact Information
Trajan Scientific and Medical
+61 (0) 3 9837 4200
PR Consultancy: LBPR
+61 (0) 429 976 718
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.